Immuron (IMRN) Shares Outstanding (Weighted Average) (2016 - 2025)
Immuron (IMRN) recorded quarterly Shares Outstanding (Weighted Average) of $888.7 million in Q3 2025, up 500.9% quarter-over-quarter from $147.9 million in Q2 2025, and little changed on a YoY basis from $885.0 million in Q3 2024.
Immuron (IMRN) Shares Outstanding (Weighted Average) (2016 - 2025) Analysis & Trends
Immuron's Shares Outstanding (Weighted Average) history runs 10 years deep, the most recent figure standing at $888.7 million for Q3 2025.
- In Q3 2025, Shares Outstanding (Weighted Average) changed 0.42% year-over-year to $888.7 million; the TTM figure through Sep 2025 stood at $888.7 million (changed 0.42% YoY), while the FY2025 annual figure was $888.7 million, changed 0.42% from the prior year.
- Shares Outstanding (Weighted Average) was $888.7 million for Q3 2025 at Immuron, up from $147.9 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $888.7 million in Q3 2025 to a low of $57.9 million in Q4 2024.
- Historically, Shares Outstanding (Weighted Average) has averaged $294.6 million across 5 years, with a median of $106.3 million in 2025.
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Weighted Average) soared 1337.97% in 2023, then plunged 89.94% in 2024.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $64.7 million in 2021, then slipped by 10.17% to $58.1 million in 2022, then surged by 890.82% to $575.7 million in 2023, then slumped by 89.94% to $57.9 million in 2024, then surged by 1434.09% to $888.7 million in 2025.
- The last three Shares Outstanding (Weighted Average) figures came in at $888.7 million (Q3 2025), $147.9 million (Q2 2025), and $57.9 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | Immuron | 921.61 Mn | 921.58 Mn | - | 888.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | 888.73 Mn |
| Jun 30, 2025 | 147.90 Mn |
| Dec 31, 2024 | 57.93 Mn |
| Sep 9, 2024 | 885.04 Mn |
| Jun 30, 2024 | 150.17 Mn |
| Dec 31, 2023 | 575.71 Mn |
| Sep 28, 2023 | 57.97 Mn |
| Aug 30, 2023 | 884.36 Mn |
| Jun 30, 2023 | 59.11 Mn |
| Dec 31, 2022 | 58.10 Mn |
| Aug 31, 2022 | 61.50 Mn |
| Jun 30, 2022 | 63.34 Mn |
| Dec 31, 2021 | 64.68 Mn |
| Jun 30, 2021 | 170.23 Mn |
| Jun 30, 2020 | 115.61 Mn |
| Dec 31, 2019 | 624.27 Mn |
| Jun 30, 2019 | 101.39 Mn |
| Dec 31, 2018 | 1,200.00 |
| Aug 30, 2018 | 58.37 Mn |
| Jun 30, 2018 | 44.19 Mn |